SOPHiA GENETICS (NASDAQ:SOPH) Chairman Jurgi Camblong Sells 17,685 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 17,685 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $5.28, for a total value of $93,376.80. Following the transaction, the chairman directly owned 3,541,122 shares in the company, valued at approximately $18,697,124.16. This trade represents a 0.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.25, for a total value of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total value of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total value of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.24, for a total value of $44,540.00.
• On Monday, April 20th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.21, for a total value of $23,372.06.
• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.00, for a total value of $87,365.00.
• On Tuesday, April 14th, Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total value of $213,919.84.
• On Monday, April 13th, Jurgi Camblong sold 4,399 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total value of $20,939.24.
• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.72, for a total transaction of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total transaction of $9,243.00.

SOPHiA GENETICS Price Performance

NASDAQ:SOPH opened at $5.51 on Thursday. The company has a market cap of $462.23 million, a P/E ratio of -10.60 and a beta of 0.96. The firm’s fifty day moving average price is $5.15 and its two-hundred day moving average price is $4.97. SOPHiA GENETICS SA has a one year low of $2.92 and a one year high of $6.30. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The company had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Institutional Trading of SOPHiA GENETICS

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Perkins Capital Management Inc. bought a new position in SOPHiA GENETICS in the fourth quarter valued at approximately $49,000. Squarepoint Ops LLC bought a new stake in SOPHiA GENETICS during the third quarter worth $49,000. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS in the 1st quarter valued at $50,000. Quadrature Capital Ltd acquired a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at $54,000. Finally, XTX Topco Ltd bought a new position in shares of SOPHiA GENETICS in the 4th quarter valued at $55,000. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The insider sales were reported as pre-planned Rule 10b5-1 transactions tied to equity vesting and tax withholding, suggesting they may be administrative rather than a reflection of weakening business fundamentals.
• Neutral Sentiment: Several insiders sold shares in the same short period, including the chairman, CEO, CFO, and other executives, which keeps investor focus on insider activity. Article Title
• Negative Sentiment: A heavy run of insider selling can still pressure shares near term because some investors may interpret it as reduced confidence or increased stock supply.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $7.50.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.